The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Dovish Draghi Sparks Off Rally Across Europe

Tue, 18th Jun 2019 16:59

(Alliance News) - An unremarkable start to the day for London stocks picked up mid-morning as dovish comments from European Central Bank President Mario Draghi boosted equities across Europe. "The Italian - who is in the endgame of his tenure at the top of the central bank - claimed both cutting interest rates and boosting its asset purchase program remain part of the ECB's tool set, comments that immediately turned a potentially fretful session into one full of triple-digit growth," observed Connor Campbell at Spreadex. Also contributing to the FTSE 100's gains on Tuesday were a well-received set of annual results from equipment rental firm Ashtead, and positive regulatory news for drugmaker AstraZeneca.The FTSE 100 index closed up 85.73 points, or 1.2%, at 7,443.04. The FTSE 250 ended up 154.18 points, or 0.8%, at 19,311.79, and the AIM All-Share closed up 0.98 of a point, or 0.1%, at 938.44.The Cboe UK 100 ended up 1.3% at 12,643.11, the Cboe UK 250 closed up 0.8% at 17,311.46, and the Cboe Small Companies ended flat at 11,643.76.ECB chief Draghi, speaking in Portugal, opened up the possibility of more stimulus measures should the economic outlook not improve and inflation not pick up in the eurozone."In the absence of improvement, such that the sustained return of inflation to our aim is threatened, additional stimulus will be required," Draghi said Tuesday at a speech at the annual ECB Forum on Central Banking in Sintra."And the APP [asset purchase programme] still has considerable headroom," he added, noting that risks to the euro area economic outlook remain tilted to the downside.US President Donald Trump, who last week complained that the European single currency is unfairly valued against the greenback, used Draghi's latest comments as a chance to slam the ECB's loose monetary policy."Mario Draghi just announced more stimulus could come, which immediately dropped the Euro against the Dollar, making it unfairly easier for them to compete against the USA," Trump tweeted.The euro stood at USD1.1193 at the European equities close Tuesday, down from USD1.1233 at the same time on Monday.Following the Sintra comments, Danske Bank said it expects the ECB to begin preparing markets for looser policy as soon as next month."We expect ECB to include 'at present or lower' levels in the July meeting, but only cut rates in September as part of a package together with restart of QE," said Danske Bank.The bank continued: "As the Sintra piece entails a sense of urgency and bold statements, we expect a 20 basis point cut in the deposit rate and the MRO rate and 25bp in the lending rate, to the new rates being negative 60bp, negative 20bp and 0% respectively."In European equities on Tuesday, the CAC 40 in Paris ended up 2.3%, while the DAX 30 in Frankfurt advanced 2.2%."Draghi's comments come just as the Fed start their two-day monetary policy meeting today and investors are starting to position themselves for a more dovish statement. Whilst a rate cut is not broadly expected today, market players believe that the Fed will start to adjust the statement to signal a rate cut either as soon as July, if not September," said Fiona Cincotta at City Index.Stocks in New York were higher at the London equities close, with the Dow Jones up 1.4%, the S&P 500 index rising 1.3%, and the Nasdaq Composite climbing 1.9%.Trump is planning an "extended meeting" with China's President Xi Jinping on the sidelines of the G20 summit in Japan at the end of June, the US President tweeted.Washington and Beijing have been locked in a trade war for months, with the US government imposing new tariffs on around half of all Chinese imports. Trump has threatened to extend these measures to all imports from China, and Beijing has threatened retaliatory measures.Trump said he had a "very good" conversation with Xi on the phone and that Washington and Beijing would start talks ahead of the summit.In the UK, the pound was quoted at USD1.2551 at the London equities close Tuesday, soft compared to USD1.2559 at the close on Monday.Conservative MPs are taking part in a second round of voting to narrow down the list of candidates standing to be new party leader and UK prime minister.Tory MPs will vote in the second bout of the contest to select Britain's next prime minister on Tuesday ahead of a live TV debate that will feature front-runner and former foreign secretary Boris Johnson.Candidates need to gain at least 33 votes from MPs to remain in the race to reach the final run-off, which will see some 160,000 Tory members select the next prime minister.If all candidates pass the 33-vote threshold, the one with the lowest total will be eliminated and by the end of the week, four of the six current riders will be forced out, leaving the final two to go head-to-head for votes from the Tory grassroots.The ongoing leadership contest comes as a poll has suggested most Conservative party members would be prepared to sacrifice the union, destroy their party, or suffer economic damage to get the UK out of the EU.The YouGov survey found that 63% of members would be prepared to see Brexit take place even if it meant Scotland leaving the UK. Some 61% would rather Brexit took place even if it caused "significant damage" to the economy, 59% would prioritise leaving the EU even if it meant Northern Ireland breaking away from the rest of the UK, and 54% would accept the Tory party "being destroyed" in order to secure Brexit.In commodities, Brent oil was quoted at USD62.56 a barrel at the London equities close Tuesday, up from from USD61.66 late Monday."Throughout 2019, there has been a largely positive correlation between oil and equities, and that is playing out today. The perception that US-China relations might improve is helping the oil market," said David Madden at CMC Markets. This caused London-listed BP to gain 2.1% and Royal Dutch Shell 'A' and 'B' shares to advance 1.4% and 1.5% respectively. Gold, meanwhile, was quoted at USD1,347.87 an ounce at the London equities close Tuesday against USD1,340.19 at the close on Monday.Back in the FTSE 100, Ashtead ended as the best blue-chip performer, up 5.7% after revealing a GBP500 million share buyback alongside a strong set of annual results. For the year to April 30, Ashtead recorded pretax profit of GBP1.06 billion, up 23% from GBP862.1 million the year before, as revenue increased 19% to GBP4.50 billion.Underlying pretax profit was up 17% to GBP1.11 billion, in line with consensus, while rental revenue was up 18% to GBP4.14 billion.Ashtead, which rents out construction and industrial equipment, said its core Sunbelt US division recorded revenue of GBP3.82 billion for the 2019 financial year versus GBP3.10 billion the year before.Drugmaker AstraZeneca advanced 2.5% after getting European approval for Lynparza in ovarian cancer.The European Commission approved the drug for adults patients with stage three and four ovarian cancer who have a BRCA mutation. BRCA1 and BRCA2 genes help suppress the growth of tumours, and mutations in these genes is associated with an increased risk of cancer.Lynparza is part of a strategic oncology collaboration between Astra and US pharma company Merck & Co, and the two companies are pursuing further ovarian cancer trials, including an ongoing trial of Lynparza in combination with bevacizumab. This is the third indication for Lynparza in the EU.International Consolidated Airlines shares ended up 1.2% after signing a deal to purchase 200 Boeing B737 short to medium-range aircraft for its fleet with deliveries set to begin in 2023.Additionally, IAG has ordered eight Airbus A321XLR aircraft for its Iberia fleet and six for Aer Lingus airline, plus 14 options.The letter of intent with Boeing - which remains subject to formal agreement - would see IAG take delivery of a mix of 737-8 and 737-10 between 2023 and 2027. The planes would be powered by the CFM Leap engines.In a separate announcement, Boeing confirmed the planes are from the troubled MAX series of the aircraft. Earlier in 2019, the 737 MAX version of the aircraft was grounded following two fatal crashes involving the plane.Boeing - with shares up 2.4% in New York - added that the deal with IAG is worth more than USD24 billion at list prices. At the bottom of the index was Premier Inn hotel owner Whitbread, down 1.3%, as the firm prepares to report first quarter results on Wednesday.Russian steelmaker Evraz ended down 2.3% after Citigroup cut the stock to Sell from Neutral.In the FTSE 250, Kier rebounded 9.4% after shedding 17% in the previous session after suspending its dividend and putting several businesses up for sale in order to control debt.In the UK corporate calendar on Wednesday, housebuilder Berkeley releases annual results alongside full-year figures from luxury bag maker Mulberry. Over-50s insurer Saga releases a trading statement. In the economic calendar on Wednesday, Japanese imports and exports for May are at 0050 BST and German produce prices are at 0700 BST, followed by the eurozone current account at 0900 BST. In the UK, produce and consumer prices are due out at 0930 BST and eurozone construction output at 1000 BST. In the US, the two-day meeting of the Federal Open Market Committee concludes with a policy decision due at 1900 BST and a press conference with Chair Jerome Powell at 1930 BST.London Close is available to subscribers as an email newsletter. Contact info@alliancenews.com

More News
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.